Navigation Links
Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results

PURCHASE, N.Y., Nov. 4 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (OTC Bulletin Board: NXXI), the developer and marketer of ingredients and finished products under the Iceland Health®, Chromax®, and Diabetes Essentials®( )brands that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory and reduce chronic joint pain, today announced financial results for the first quarter of fiscal year 2010 ended September 30, 2009.

The Company reported total revenues of $4.6 million for the first quarter ended September 30, 2009, compared to $12.7 million in the corresponding quarter a year ago. Net loss for the first quarter this year was $0.6 million, or $(0.01) per diluted common share, compared to net income of $0.2 million, or $0.00 per diluted common share, in the first quarter a year ago.

The Company's continuing emphasis on controlling its expenses reduced operating expenses by $3.9 million, or 62%, from $6.3 million in the first quarter last year to $2.4 million in the first quarter this year. The reduction in expenses was the primary reason for the Company's $0.4 million operating profit for the first quarter of this fiscal year.

Michael Zeher, president and chief executive officer, said, "While economic conditions continue to be extremely challenging, we are aggressively managing our expenses and, as a result, were profitable on an operating basis in the first quarter. We also continue to work diligently to arrange new financing to replace the current line that we will pay off on November 15, 2009. Moreover, we continue to work with the Iceland Health principals to reach an accommodation on the $2.5 million plus interest that we owe them and secured with the Iceland Health trademark."

"Additionally, in the first quarter we signed a non-binding letter of intent for the sale of certain assets and liabilities of our retail and direct response businesses to a privately-owned company," continued Mr. Zeher. "We will announce the terms of the proposed sale if the transaction proceeds and a binding agreement is signed. Proceeds from the sale of these assets would improve the Company's short-term financial situation, and would allow us to refocus our efforts on growing our consistently profitable ingredients business.

"There are many nutritional products, supplements, pharmaceuticals, and animal feed products that can be enhanced by the addition of our patented ingredients. We look forward to developing these new business opportunities both here in the U.S. and abroad. Accordingly, we're pleased to note that our chromium picolinate product was recently approved for use as an ingredient in the European Union markets.

"In short, we are working to alleviate our current financial situation and to gradually become a profitable company. We plan to grow the business with more focused and streamlined operations, an improved balance sheet, and consistently positive cash flow. "

About Nutrition 21

Nutrition 21, Inc. (OTC BB: NXXI.OB), headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health and wellness products include: Iceland Health Chromax®, Iceland Health Advanced Memory Formula(TM), Diabetes Essentials(TM), Iceland Health® Maximum Strength Omega-3 and Iceland Health® Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center retailers as well as internationally. For more information please visit

Safe Harbor Provision

This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission, including its Form 10-K/A for the year ended June 30, 2009. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.

                                 NUTRITION 21, INC.
                           CONSOLIDATED BALANCE SHEETS
                               (Dollars in thousands)

                                                       September 30, June 30,
                                                            2009        2009
                                                            ----        ----
                                                        (unaudited)  (Note 1)
    Current assets:
       Cash and cash equivalents                            $592      $1,373
       Accounts receivable, net                            2,357       2,752
       Other receivables, net                                 90         516
       Inventories, net                                    3,582       3,878
       Other current assets                                  264         467
    Property and equipment, net                               44          46
    Patents, trademarks and other intangibles, net           750         766
    Goodwill and other intangibles with indefinite lives   3,636       3,636
    Other assets                                           1,116       1,389
                                                           -----       -----
    TOTAL ASSETS                                         $12,431     $14,823
                                                         =======     =======

    Short-term borrowings                                 $3,070      $4,457
    Accounts payable                                       4,068       4,439
    Accrued expenses                                       1,540       2,218
    Deferred income                                          144         361
    Deferred income taxes                                  1,200       1,200

    8% Series J convertible preferred stock subject to
     mandatory redemption                                 13,658      13,218
                                                          ------      ------

              Total liabilities                           23,680      25,893
                                                          ------      ------
    Stockholders' Deficit                                (11,249)    (11,070)
                                                        --------    --------
    TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT          $12,431     $14,823
                                                         =======     =======

                                NUTRITION 21, INC.
                 (in thousands, except share and per share data)

                                                        Three Months
                                                        September 30,
                                                    2009           2008
                                                    ----           ----

    Net sales                                     $4,542        $12,609
    Other revenues                                    94             51
                                                     ---            ---
    Total Revenues                                 4,636         12,660
                                                   -----         ------
    Costs and Expenses

    Cost of Revenues                               1,813          4,745

    Advertising and Promotion                      1,303          5,362

    General and Administrative                       980            798

    Research and Development                          79             80

    Depreciation and Amortization                    105            363
                                                     ---            ---

    Total Costs and Expenses                       4,280         11,348
                                                   -----         ------

    Operating Profit                                 356          1,312

    Interest income (expense), net                  (999)        (1,098)
                                                   -----        -------

    (Loss) income before income taxes               (643)           214

    Income taxes                                      --             --
                                                   -----          -----

    Net (loss) income                              $(643)          $214
                                                  ======           ====

    Basic and diluted (loss) earnings per
     common share                                 $(0.01)         $0.00
                                                 =======          =====

    Weighted average number of common shares
     - basic and diluted                     $72,455,162    $64,134,052
                                             ===========     ==========

        Nutrition 21, Inc.          Lytham Partners, LLC
        Alan Kirschbaum             Joe Diaz, Joe Dorame, Robert Blum
        914-701-4500                602-889-9700

SOURCE Nutrition 21, Inc.

SOURCE Nutrition 21, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IOM recommends new nutritional requirements for school meal programs
2. Fitness Nutritions Amino Acid Complex Olympic Champion Dara Torres Calls The Best Product Ive Ever Used, Selects TransMedia for PR
3. For Older Adults, Good Nutrition and Exercise Are Key To Staying Healthy & Active
4. Nutrition Still Not A Grade in U.S. Schools: Studies
5. Bariatric Advantage Re- Launches ProMend ABG Designed to Nutritionallly Support Pre and Post Plastic Reconstructive Surgery Patient
6. Compatible Technology International Project to Enhance Child Nutrition and Livelihoods of Rural Families in Malawi and Tanzania
7. Protica Teams With UNFI/Select Nutrition to distribute All-Natural Protein Shot, Proasis
8. Innovative New Book Series Encourages Kids to Go Behind Their Parents' Backs and Listen to Experts on Important Health and Wellness, Education, Personal Finance and Nutrition
9. Senior Living Residences Launches Innovative Nutrition Program to Promote Cognitive Health and Lower the Risk of Alzheimers Disease
10. Frost & Sullivan Cites Arm & Hammer for Excellence in the Dairy Animal Nutrition and Management Market
11. People with type 2 diabetes not meeting important nutritional recommendations
Post Your Comments:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... PHILADELPHIA , Oct. 2, 2017 Halo Labs announces ... particle analysis system called the HORIZON at MIBio 2017 in ... analyzes subvisible and visible particulate matter in biopharmaceutical samples with unprecedented ... use of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: